Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus TEPYLUTE.
CYCLOPHOSPHAMIDE vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic metabolism by cytochrome P450 (CYP2B6, CYP3A4, CYP2C9) to form active metabolites, phosphoramide mustard and acrolein, which alkylate DNA and inhibit protein synthesis.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
400-600 mg/m2 IV every 2-4 weeks; or 50-100 mg/m2 orally daily for 7-14 days; or 1-2 g/m2 IV as a single dose every 3-4 weeks.
100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 4-8 hours in adults with normal renal function; prolonged in renal impairment (up to 15 hours) and in children.
Clinical Note
moderateCyclophosphamide + Verteporfin
"Cyclophosphamide may increase the cardiotoxic activities of Verteporfin."
Clinical Note
moderateCyclophosphamide + Digoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCyclophosphamide + Digitoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCyclophosphamide + Deslanoside
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal: approximately 30-60% of dose excreted unchanged in urine; biliary/fecal excretion is minimal (<5%).
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent
"Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside."